Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5565-5575

  Cha, Kwang Ho ^a,b   Cho, Kyung Jin ^b   Kim, Min Soo ^c   Kim, Jeong Soo ^b   Park, Hee Jun ^a,b   Park, Junsung ^a,b   Cho, Wonkyung ^a,b   Park, Jeong Sook ^b   Hwang, Sung Joo ^a  

^a Yonsei University   (South Korea)

^b Chungnam National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bioavailability; Fenofibrate; Melt adsorption; Supercritical CO2

Indexed keywords

ATTAPULGITE; CARBON DIOXIDE; FENOFIBRATE; SOLVENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MELTING POINT; NONHUMAN; PARTICLE SIZE; POWDER; RAT; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; X RAY DIFFRACTION;

ADSORPTION; ALUMINUM SILICATES; ANIMALS; BIOLOGICAL AVAILABILITY; CARBON DIOXIDE; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG COMPOUNDING; FENOFIBRATE; HOT TEMPERATURE; HYPOLIPIDEMIC AGENTS; MAGNESIUM; MALE; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOCAPSULES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 84870357419     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S36939     Document Type: Article

References (34)

1. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia. Drugs. 1997;54:615-633.
2. Murakami H, Murakami R, Kambe F, etal. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophy Res Commun. 2006;341:973-978.
3. Jinno J, Kamada N, Miyake M, etal. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56-64.
4. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86:1-12.
5. Van Nijlen T, Brennan K, Van den Mooter G, Blaton N, Kinget R, Augustijns P. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm. 2003;254:173-181.
6. Rasenack N, Mueller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19:1894-1900.
7. Kim M-S, Lee S, Park J-S, Woo J-S, Hwang S-J. Micronization of cilostazol using supercritical antisolvent (SAS) process: effect of process parameters. Powder Technol. 2007;177(2):64-70.
8. Heike F, Bernd F, Karl K, Roland B. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm. 2006;62:171-177.
9. Sharma S, Sher P, Badve S, Pawar AP. Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation. AAPS Pharm Sci Tech. 2005;6:618-625.
10. Sher P, Ingavle G, Ponrathnam S, Pawar AP. Low density porous carrier: drug adsorption and release study by response surface methodology using different solvents. Int J Pharm. 2007;331:72-83.
11. Subramaniam B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci. 1997;86:885-890.
12. Jun SW, Kim M-S, Kim J-S, etal. Preparation and characterization of simvastatin/hydroxypropyl-[beta]-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2007;66:413-421.
13. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Biopharm. 2006;27:299-310.
14. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm. 2008;360:213-218.
15. Fischer K, Wilken M, Gmehling J. The effect of gas pressure on the melting behavior of compounds. Fluid Phase Equilib. 2003;210:199-214.
16. Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci. 2003;92:536-551.
17. Gupta MK, Goldman D, Bogner RH. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. Pharm Dev Technol. 2001;6:563-572.
18. Tandya A, Dehghani F, Foster NR. Micronization of cyclosporine using dense gas techniques. J Supercrit Fluids. 2006;37:272-278.
19. Hussein K, Turk M, Wahl MA. Drug loading into [beta]-cyclodextrin granules using a supercritical fluid process for improved drug dissolution. Eur J Pharm Sci. 2008;33:306-312.
20. 2for a novel melt dispersion micronization process. J Mol Liq. 2007;131:53-59.
21. Strumendo M, Bertucco A, Elvassore N. Modeling of particle formation processes using gas saturated solution atomization, J Supercrit Fluids. 2007;41:115-125.
22. Kerc J, Srcic S, Knez Z. Micronization of drugs using supercritical carbon dioxide. Int J Pharm. 1999;182:33-39.
23. Chen Y-M, Lin P-C, Tang M, Chen Y-P. Solid solubility of antilipemic agents and micronization of gemfibrozil in supercritical carbon dioxide. J Supercrit Fluids. 2010;52:175-182.
24. Heinz A, Gordon KC, McGoverin CM, Rades T, Strachan CJ. Understanding the solid-state forms of fenofibrate-a spectroscopic and computational study. Eur J Pharm Biopharm. 2009;71:100-108.
25. Srinarong P, Faber JH, Visser MR, Hinrichs WLJ, Frijlink HW. Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm. 2009;73:154-161.
26. Sliwinska-Bartkowiak M, Dudziak G, Gras R, Sikorski R, Radhakrishnan R, Gubbins KE. Freezing behavior in porous glasses and MCM-41. Colloids Surf A Physicochem Eng Asp. 2001;187/188: 523-529.
27. Shen SC, Ng WK, Chia L, Dong YC, Tan RB. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. J Pharm Sci. 2009;99:1997-2007.
28. Wakayama H, Goto Y, Fukushima Y. A novel method for tailoring porous structures of nanoporous materials using supercritical solvents. Phys Chem Chem Phys. 2003;5:3784-3788.
29. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biopharm. 2004;57:533-540.
30. Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008;359:211-219.
31. Kim MS, Jin SJ, Kim JS, etal. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69:454-465.
32. Sugimoto M, Okagaki T, Narisawa S, Koida Y, Nakajima K. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int J Pharm. 1998;160:11-19.
33. Yamashita K, Nakate T, Okimoto K, etal. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267:79-91.
34. Vaughn JM, McConville JT, Crisp MT, Johnston KP, Williams RO. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev Ind Pharm. 2006;32:559-567.